Institut fuer Frauengesundheit
Institut fuer Frauengesundheit
Explore linked clinical trials.6 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| ESR1Real World Assessment Prevalence Study | HR+/HER2- aBC Undergoing 1L Treatment With CDK4/6i (Palbociclib, Abemaciclib or Ribociclib) and AI (Anastrozole or Letrozole) | Not yet recruiting | Not applicable | 2026-09-14 | NCT07817212 | |
| IMPLEMENTING PATIENTS' COMPETENCE IN ORAL EBC THERAPY PERSISTENCE | HR+/HER2- Early Breast Cancer | Not yet recruiting | Not applicable | 2026-09-10 | NCT07521202 | |
| Evaluating the Effectiveness of Typology-based Coaching on Patients' Therapy Management | HR+/HER2- Early Breast Cancer | Recruiting | Not applicable | 2026-07-16 | NCT07708571 | |
| Patient Relevant Outcomes Improvement Program in High Risk Hormone Receptor Positive (HR+) Breast Cancer | HR+/HER2- Early Breast Cancer | Recruiting | Not stated | 2026-05-14 | NCT07531693 | |
| Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2024-05-07 | NCT05033756 | |
| Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, hormone receptor-positive breast cancer, neoplasm, skin disorder | Recruiting | Phase 4 | 2023-04-18 | NCT05452213 |